PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.
The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb. Over time, the company plans to expand further within the same location. Current staff will move from North Brunswick to Princeton, and the facility will be fully operational by July 1, 2021. NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.
“On behalf of the board of directors and senior management at NJ Bio, I am excited to announce this move,” said Nareshkumar Jain, Ph.D., President and CEO of NJ Bio. “Our expansion to this advanced facility demonstrates the rapid growth of NJ Bio in just over two years. This new location, well-equipped with the latest instruments, and staffed by exceptional scientists, will ensure that NJ Bio continues to remain an outstanding partner to our clients, delivering high value and results for their most challenging research and development needs.”
About NJ Bio
NJ Bio is an integrated chemistry service provider with expertise in bioconjugation, payload-linker synthesis, nucleotide chemistry, and application of BioNMR to drug discovery programs, including protein degraders. NJ Bio also offers expertise in flow chemistry and process development and provides innovative solutions for large-scale continuous manufacturing needs. NJ Bio’s clients range from large pharmaceutical and biotechnology companies to start-ups.
For additional information, visit www.njbio.com.
